Literature DB >> 8791250

Intellectual impairment in neurofibromatosis 1.

R E Ferner1, R A Hughes, J Weinman.   

Abstract

Intellectual problems are a recognized feature of neurofibromatosis 1 (NF1) but their aetiology is unknown. We investigated the frequency, nature, severity and cause of intellectual impairment in NF1. We undertook neurological and psychometric assessments on 103 patients with NF1 and 105 controls equated for age, sex and socio-economic status. The mean full scale IQ was significantly lower in the NF1 than the control group, 88.6 (SD 14.6) compared with 101.6 (SD 14.2). However, the degree of intellectual impairment was mild and only 8% of NF1 patients had an IQ < 70. The NF1 patients also had significantly poorer reading skills and impaired short term memory. On a computerized performance test battery of complex tasks, the NF1 group had significantly slower mean reaction times and higher error rates than the controls. Overall the patients displayed impaired attention and were slow to develop and adapt strategies for complex and unfamiliar tasks. A particular profile of intellectual deficit did not emerge. The presence of neurological and/or medical complications was weakly associated with a lower mean full scale IQ in NF1 patients. Socio-demographic factors, age or sex differences and the presence of macrocephaly did not contribute to neurocognitive deficit in NF1.

Entities:  

Mesh:

Year:  1996        PMID: 8791250     DOI: 10.1016/0022-510x(96)00022-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  29 in total

Review 1.  Neurology and the skin.

Authors:  O Hurko; T T Provost
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-04       Impact factor: 10.154

2.  A child with axillary freckling and café au lait spots.

Authors:  Stephen Wainer
Journal:  CMAJ       Date:  2002-08-06       Impact factor: 8.262

3.  Health Survey of Adults with Neurofibromatosis 1 Compared to Population Study Controls.

Authors:  Krister W Fjermestad; Livø Nyhus; Øivind J Kanavin; Arvid Heiberg; Lise B Hoxmark
Journal:  J Genet Couns       Date:  2018-02-10       Impact factor: 2.537

4.  The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults.

Authors:  Hilda A Crawford; Belinda Barton; Meredith J Wilson; Yemima Berman; Valerie J McKelvey-Martin; Patrick J Morrison; Kathryn N North
Journal:  J Genet Couns       Date:  2015-04-19       Impact factor: 2.537

5.  A case of neurofibromatosis and multiple sclerosis.

Authors:  Gabriella Spinicci; Maria Valeria Cherchi; Raffaele Murru; Maria Conti; Maria Giovanna Marrosu
Journal:  Neurol Sci       Date:  2010-04-28       Impact factor: 3.307

6.  Abnormal relationship between GABA, neurophysiology and impulsive behavior in neurofibromatosis type 1.

Authors:  Maria J Ribeiro; Inês R Violante; Inês Bernardino; Richard A E Edden; Miguel Castelo-Branco
Journal:  Cortex       Date:  2014-11-11       Impact factor: 4.027

Review 7.  Neurocognitive dysfunction in children with neurofibromatosis type 1.

Authors:  Tena L Rosser; Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

Review 8.  Guidelines for the diagnosis and management of individuals with neurofibromatosis 1.

Authors:  Rosalie E Ferner; Susan M Huson; Nick Thomas; Celia Moss; Harry Willshaw; D Gareth Evans; Meena Upadhyaya; Richard Towers; Michael Gleeson; Christine Steiger; Amanda Kirby
Journal:  J Med Genet       Date:  2006-11-14       Impact factor: 6.318

9.  Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT.

Authors:  Vanessa L Merker; Sarah McDannold; Eric Riklin; Mojtaba Talaei-Khoei; Monica R Sheridan; Justin T Jordan; Scott R Plotkin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2017-11-08       Impact factor: 4.130

10.  Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (Nf1) tumor suppressor.

Authors:  T A Rizvi; S Akunuru; G de Courten-Myers; R C Switzer; M L Nordlund; N Ratner
Journal:  Brain Res       Date:  1999-01-16       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.